Caladrius Biosciences to Present at Upcoming February Conferences
February 05 2019 - 8:00AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company with multiple technology platforms targeting select
cardiovascular indications and autoimmune disease, announced today
that management will present at the following conferences in
February:
2019 BIO CEO & Investor Conference
Date & Time: |
Tuesday, February 12,
2019 at 9:30 a.m. (EST) |
Presenter: |
David Mazzo, Ph.D.,
President and Chief Executive Officer |
Venue: |
New York Marriott
Marquis in New York City |
A live and archived webcast of Dr. Mazzo’s presentation will be
available under the Investor Relations section of the Company’s
website at www.caladrius.com.
Japan Endovascular Treatment Conference of
2019
Title: |
Latest treatment
strategy for CLI (including information of CLBS12 trial) |
Date
& Time: |
Friday, February 22,
2019 at 12:10 p.m. (JST) |
Presenter: |
Douglas Losordo, M.D.,
FACC, FAHA, Executive Vice President, Global Head of Research and
Development, Chief Medical Officer |
Venue: |
TKP Garden City
Shinagawa in Tokyo, Japan |
About Caladrius Biosciences
Caladrius is a late-stage therapeutics development
biopharmaceutical company committed to the development of
innovative products that have the potential to restore the health
of people with chronic illnesses. Our leadership team collectively
has decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other
areas. The Company’s goal is to build a broad portfolio
of novel and versatile products that address important unmet
medical needs. Our current product candidates include three
developmental treatments for cardiovascular diseases based on our
CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE
designation, in Phase 2 testing in Japan and eligible for early
conditional approval for the treatment of critical limb ischemia;
CLBS14-CMD, in Phase 2 testing for the treatment of coronary
microvascular dysfunction and CLBS14-NORDA (formerly CLBS14-RfA) in
late-stage development for no option refractory disabling angina
for which it has received RMAT designation. Caladrius’ autoimmune
product candidate in Phase 2 testing, CLBS03, is an ex
vivo expanded polyclonal T regulatory cell therapy for the
treatment of recent-onset type 1 diabetes. CLBS03 has been awarded
Fast Track and Orphan designations by the FDA. For more
information on the company, please visit www.caladrius.com.
Contact:
Caladrius Biosciences, Inc.John MendittoVice President, Investor
Relations and Corporate CommunicationsPhone:
+1-908-842-0084Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024